Clinical Trial Update: Safety and Dose-escalation Study of AAV2-hCHM in Participants With CHM (Choroideremia) Gene Mutations [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 safety and dose-escalation study of AAV2-hCHM for CHM-related choroideremia completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Choroideremia

Drugs mentioned

• AAV2-hCHM (AAV2-hCHM)

Snippet

Sponsor: Spark Therapeutics, Inc. | Conditions: Choroideremia, CHM (Choroideremia) Gene Mutations | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2023-11-02